Premium
Therapeutic effects of molecularly designed antigen UREB138 for mice infected with Helicobacter pylori
Author(s) -
Morihara Fumiko,
Hifumi Emi,
Yamada Manabu,
Nishizono Akira,
Uda Taizo
Publication year - 2008
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.21804
Subject(s) - helicobacter pylori , microbiology and biotechnology , antigen , vaccination , urease , gastritis , biology , bacteria , immunization , immune system , recombinant dna , immunology , enzyme , gene , biochemistry , genetics
Helicobacter pylori ( H. pylori ) is a bacteria that is well known as the principal cause of chronic gastritis and peptic ulcer disease in humans. Because no effective vaccine has yet been established, we designed a new biomolecule as a vaccination antigen capable of preventing the infection of H. pylori . The designed biomolecule involves a 138 stretch (aa 201–aa 338 of β‐subunit of H. pylori urease), which is the functionally important region for urease activity. The region was expressed as a recombinant protein, called UREB138. The therapeutic vaccination was performed using UREB138 in mice persistently infected with H. pylori . The subcutaneous administration of UREB138 remarkably reduced the number of bacteria in the mice stomach compared with the control. Immunization with UREB138 enhanced the urease‐specific IgA and IgG1 in the serum. Immunohistochemical staining for IgA in gastric mucosa showed that the number of mice positively stained with IgA was significantly higher in UREB138‐immunized mice than in control mice. Furthermore, the expression of interferon‐gamma mRNA in the gastric tissues with eradicated bacteria was higher than in the non‐eradicated group. The combination of Th1‐ and Th2‐mediated immunity plays a role in reducing the colonization of bacterial numbers of H. pylori . Biotechnol. Bioeng. 2008;100: 634–643. © 2008 Wiley Periodicals, Inc.